Moreover, in myeloproliferative neoplasms (MPN), aberrant JAK2 signaling plays a crucial tumor-promoting role, while JAK inhibitors did not induce patient remission; alternatively, simvastatin, lovastatin and atorvastatin inhibited mutated JAK2 localization to lipid rafts, consequently inhibited JAK2-V617-dependent growth and induced apoptosis in MPN cells, and suppressed primary erythroid colony formation of primary cells from MPN patients (Griner et al., 2013). This evidence concerns the gene JAK2 and myeloproliferative disorder.